Novartis Ag

Novartis Corporation

Claudia Betschart

Junichi Sakaki

Rene Lattmann

Martin Missbach

Naoki Teno

Yves Auberson

Marina Tintelnot-Blomley

Siem Jacob Veenstra

Eva Altmann

Genji Iwasaki

Kenji Hayakawa

Osamu Irie

Rainer Machauer

Thomas Josef Troxler

Dirk Behnke

Silvio Ofner

Vinod Shashikant Chaudhari

Chetan Pandit

Simona Cotesta

Sangamesh Badiger

Kurt Laumen

Ralf Glatthar

Kaspar Zimmermann

John Henry Van Duzer

Robert Mah

Stefanie Flohr

Clive McCarthy

Walter Schilling

Ruben Alberto Tommasi

Leslie Wighton McQuire

Marc Gerspacher

Jürgen Wagner

Oliver Simic

Manuel Koller

Andreas Von Sprecher

Eric Vangrevelinghe

Siem J Veenstra

Samuel Hintermann

Silvio Roggo

Murali Chebrolu

Andreas Lerchner

Jürgen Hans-Hermann Hinrichs

Paul David Greenspan

Scott Douglas Cowen

Keigo Gohda

Miyuki Horiuchi

Michihiro Takai

Arndt Meyer

Sangamesch Badiger

Simona Costesta

The invention relates to compound of the formula (I') in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. 

Disubstituted heteroaryl-fused pyridines

The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. 

Diaza-spiro[5.5]undecanes

The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Macrocyclic compounds useful as BACE inhibitors

The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

Heteroaryl nitrile derivatives

The present invention pertains to novel dibenzo[b,f]oxepine-10-carboxamides compound to a process for the preparation of such compounds of formula I, their use as a pharmaceuticals, especially in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, and to pharmaceutical compositions and combinations comprising such compounds of formula I.

Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof

The present invention relates to novel macrocyclic compounds of the formula wherein R, R, R, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Macrocyclic lactams and pharmaceutical use thereof

The invention provides compounds of Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors. 

Hetereoaryl nitrile derivatives

The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors. 

Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Dipeptide nitriles

1-aryl-2-acylamino-ethane compounds and their use as neurokinin

Base-substituted debenz�b,f!oxepines of formula I ##STR1## wherein alk is a divalent aliphatic radical, R is an amino group that is unsubstituted or mono- or di-substituted by monovalent aliphatic and/or araliphatic radicals or disubstituted by divalent aliphatic radicals, and R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each, independently of the others, hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and pharmaceutically acceptable salts thereof, may be used as anti-neurodegenerative active ingredients of medicaments. The invention relates also to novel compounds of formula I.

Anti-neurodegeneratively active 10-aminoaliphatyl-dibenzi �b,f! oxepines

Base-substituted dibenz�b,f!oxepines of formula I ##STR1## wherein alk is a divalent aliphatic radical, R is an amino group that is unsubstituted or mono- or di-substituted by monovalent aliphatic and/or araliphatic radicals or disubstituted by divalent aliphatic radicals, and R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each, independently of the others, hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and pharmaceutically acceptable salts thereof, may be used as anti-neurodegenerative active ingredients of medicaments. The invention relates also to novel compounds of formula I.

Treatment method using anti-neurodegeneratively active

Growing community of inventors

Basel, Switzerland

Claudia Betschart